Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
AssigneeJanssen Pharmaceutica NV
InventorsLinda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Methods of identifying anti-VISTA antibodies capable of eliciting certain biological responses are also included.
Claims14
A method of eliciting a biological response in a subject, comprising administering to the subject an antibody that binds a V-domain Ig Suppressor of T cell Activation (VISTA) protein, or an antigen-binding fragment thereof, in an amount sufficient to elicit a biological response in the subject, wherein the biological response is selected from the group consisting of:
- a) a decrease in the number of circulating immune cells;
- b) a decrease in the number of granulocytes in bone marrow and spleen;
- c) an increase in the number of neutrophils, macrophages, T cells, or a combination thereof in a tumor microenvironment;
- and
- d) an increase in the level of one or more cytokines;
- or
- e) a combination thereof.
3-7. (canceled)
(canceled)
(canceled)
The method of claim 41, wherein the subject is a human, rodent or non-human primate.
13-14. (canceled)
(canceled)
A method of identifying an antibody that binds a V-domain Ig Suppressor of T cell Activation (VISTA) protein and elicits a biological response, comprising:
- a) providing an antibody that binds VISTA, or an antibody fragment thereof, to a cell, tissue, organ or organism;
- and
- b) determining whether the antibody or antibody fragment thereof induces a biological response in the cell, tissue, organ or organism, wherein the biological response is selected from the group consisting of:
- i) activation of monocytes;
- ii) activation of T cells;
- iii) a decrease in the number of circulating immune cells;
- iv) a decrease in the number of granulocytes in bone marrow and spleen;
- v) an increase in the number of neutrophils, macrophages or both in a tumor microenvironment;
- and
- an increase in the level of one or more cytokines;
- or a combination thereof.
19-34. (canceled)
Dependencies are inferred from the claim text.